Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stock Holdings Increased by Toronto Dominion Bank

Toronto Dominion Bank raised its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBHGet Rating) by 25.4% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 142,465 shares of the medical equipment provider’s stock after buying an additional 28,848 shares during the quarter. Toronto Dominion Bank owned about 0.07% of Zimmer Biomet worth $18,099,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Russell Investments Group Ltd. raised its stake in Zimmer Biomet by 2.4% during the third quarter. Russell Investments Group Ltd. now owns 200,923 shares of the medical equipment provider’s stock valued at $29,413,000 after buying an additional 4,699 shares in the last quarter. Pura Vida Investments LLC raised its stake in Zimmer Biomet by 30.0% during the third quarter. Pura Vida Investments LLC now owns 65,000 shares of the medical equipment provider’s stock valued at $9,513,000 after buying an additional 15,000 shares in the last quarter. Sentry Investment Management LLC raised its stake in Zimmer Biomet by 1,263.2% during the third quarter. Sentry Investment Management LLC now owns 1,963 shares of the medical equipment provider’s stock valued at $287,000 after buying an additional 1,819 shares in the last quarter. Alliancebernstein L.P. raised its stake in Zimmer Biomet by 4.5% during the third quarter. Alliancebernstein L.P. now owns 2,267,109 shares of the medical equipment provider’s stock valued at $331,814,000 after buying an additional 97,096 shares in the last quarter. Finally, American Century Companies Inc. raised its stake in Zimmer Biomet by 15.1% during the third quarter. American Century Companies Inc. now owns 4,259,604 shares of the medical equipment provider’s stock valued at $623,436,000 after buying an additional 557,891 shares in the last quarter. Hedge funds and other institutional investors own 89.02% of the company’s stock.

ZBH has been the subject of several recent research reports. Zacks Investment Research raised Zimmer Biomet from a “sell” rating to a “hold” rating and set a $133.00 target price for the company in a report on Wednesday, April 13th. StockNews.com lowered Zimmer Biomet from a “buy” rating to a “hold” rating in a report on Friday, April 8th. Canaccord Genuity Group lowered Zimmer Biomet from a “buy” rating to a “hold” rating and lowered their target price for the company from $165.00 to $125.00 in a report on Tuesday, February 8th. Bank of America initiated coverage on Zimmer Biomet in a report on Tuesday, March 1st. They set an “underperform” rating and a $120.00 target price for the company. Finally, Loop Capital lowered Zimmer Biomet from a “buy” rating to a “hold” rating and set a $130.00 target price for the company. in a report on Wednesday, March 2nd. Two research analysts have rated the stock with a sell rating, sixteen have given a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $143.58.

In other news, VP Chad F. Phipps sold 35,149 shares of the stock in a transaction on Thursday, March 17th. The stock was sold at an average price of $121.97, for a total transaction of $4,287,123.53. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.73% of the stock is currently owned by corporate insiders.

NYSE ZBH traded down $0.75 on Monday, reaching $125.25. 12,661 shares of the stock traded hands, compared to its average volume of 1,880,846. The firm’s fifty day simple moving average is $122.98 and its 200 day simple moving average is $128.67. The company has a quick ratio of 0.72, a current ratio of 1.41 and a debt-to-equity ratio of 0.43. The company has a market cap of $26.22 billion, a price-to-earnings ratio of 66.32, a P/E/G ratio of 3.30 and a beta of 1.20. Zimmer Biomet Holdings, Inc. has a 12 month low of $108.47 and a 12 month high of $180.36.

Zimmer Biomet (NYSE:ZBHGet Rating) last announced its quarterly earnings data on Monday, February 7th. The medical equipment provider reported $1.95 EPS for the quarter, missing analysts’ consensus estimates of $1.98 by ($0.03). Zimmer Biomet had a net margin of 5.12% and a return on equity of 12.30%. The company had revenue of $2.04 billion for the quarter, compared to analyst estimates of $2.07 billion. During the same quarter last year, the company posted $2.11 EPS. Zimmer Biomet’s revenue was down 2.3% on a year-over-year basis. As a group, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 6.54 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 29th. Stockholders of record on Tuesday, March 29th will be given a dividend of $0.24 per share. The ex-dividend date is Monday, March 28th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.77%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 50.53%.

About Zimmer Biomet (Get Rating)

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company designs, manufactures, and markets orthopaedic reconstructive products, such as knee and hip products; S.E.T.

See Also

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBHGet Rating).

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.